Skip to main content

Table 5 Multinomial logistic regression model: Prediction of Response (second-line)

From: Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer

Factor p = OR 95% CI
Age > 65 years 0.392 0.35 0.03-3.9
Age < 35 years 0.363 0.3 0.02-4
Stage 4 at diagnosis 0.839 1.11 0.4-3.14
Grading (1,2 versus 3) 0.268 0.37 0.06-2.15
Histologic type (ductal versus lobular) 0.19 0.17 0.01-2.41
Positive hormone receptor status 0.534 0.63 0.15-2.68
Time to recurrence < 12 months 0.332 0.43 0.08-2.36
Visceral metastases 0.147 3.96 0.62-25-35
Number of metastatic sites (1 versus 2) 0.318 0.36 0.05-2.64
Number of metastatic sites (2 versus > 2) 0.792 0.82 0.18-3.63
Trastuzumab from first-line palliative treatment 0.886 1.15 0.18-7.53
Response to fist-line trastuzumab-based therapy 0.201 2.58 0.6-11-08
New metastatic sites at progression upon first-line trastuzumab-based therapy 0.953 1.04 0.28-3.84